Several groundbreaking treatments are revolutionizing diabetes treatment, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide being highlighted leading candidates. Retatrutide, a dual GIP and GLP-1 target agonist, exhibits significant body mass decrease and enhanced glucose levels. Cagrillintide, one GLP-1 agonist, is presently in clinica